MedTrace Logo

Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205

NCT01247922 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2024-12-06

Study results available
· View outcomes & findings →

Summary

Participants that were assigned to the oral etoposide treatment arm in protocol OSI-774-205 and either progressed while on study or discontinued due to unacceptable toxicity related to etoposide were allowed to participate in this study to assess the safety profile of single-agent erlotinib in participants with recurrent or refractory pediatric ependymoma.

Conditions

Interventions

DRUG

Erlotinib

continuous oral Erlotinib 85 mg/m\^2 per day

Sponsors & Collaborators

  • OSI Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Astellas Pharma Global Development

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Year
Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-23
Primary Completion
2012-09-13
Completion
2012-09-13

Countries

  • United States
  • Canada
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01247922 on ClinicalTrials.gov